We read with interest the article entitled anti-TNF immnosuppressive treatments, such as Gut August 2014 Vol 63 No 8 1367.

Beside these identified disease understanding of inflammation: implications for the understanding of inflammatory bowel disease’ written by Uhlig1 and published by Gut. The study, describing the very early onset of intestinal inflammation in several orphan monogenic diseases, aimed at determining the presence of a link between the IBD-like phenotype shown by these rare diseases and the intestinal inflammation seen in typical IBD. The IBD aetiology is multifactorial: at present, genome-wide association studies have identified 163 susceptibility loci associated with an increased risk of developing IBD.2

In his article,1 Uhlig reports that children with very early onset of bowel inflammation may present a different phenotype and a different genetic architecture. In particular, these children can be classified either as classical IBD patients or as patients suffering from monogenic diseases, the latter also carrying a high number of genetic variants associated with susceptibility to develop IBD. In this regard, we wish to focus the attention on six patients suffering from mevalonate kinase deficiency (MKD, OMIM #260920), diagnosed during the first year of life and followed-up at the Institute for Maternal and Child Health—IRCCS ‘Burlo Garofolo’ (Trieste, Italy). MKD, caused by inherited recessive mutations in the mevalonate kinase gene (MVK), is characterised by febrile attacks, often associated with abdominal pain, diarrhoea and vomiting; it can be considered as an auto-inflammatory defect predisposing to IBD-like intestinal inflammation.3 4 The six MKD patients were homozygous and/or heterozygous for missense mutations on the MVK gene (table 1).

Abdominal pain arose in all MKD patients within the first year of life, with high values of both C reactive protein and erythrocyte sedimentation rate, and very frequent episodes of diarrhoea. Patients exhibit heterogeneous phenotypes: some are more severe and respond poorly to conventional drugs, while others are mild and respond quite well to treatments (anaakinra, canakinumab, etanercept), despite carrying the same MVK mutations.

We decided to further explore the hypothesis that MKD can be considered a monogenic cause of early onset pathologies with IBD-like symptoms. A whole exome sequencing analysing was carried out on the same six MKD patients followed-up at our children hospital, searching for genetic variants associated with chronic IBD. Exome enrichment was performed by TruSeq Exome Enrichment 62Mb (Illumina); sequence data were produced using Illumina HiSeq 1000 with 100-bp paired-end reads and analysed by CLC Genomics Workbench V6.5 software.

The variants (table 2) were identified in genes known to be associated with IBD

Dear editor,

We read with interest the article entitled ‘Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease’ written by Uhlig1 and published by Gut. The study, describing the very early onset of intestinal inflammation in several orphan monogenic diseases, aimed at determining the presence of a link between the IBD-like phenotype shown by these rare diseases and the intestinal inflammation seen in typical IBD. The IBD aetiology is multifactorial: at present, genome-wide association studies have identified 163 susceptibility loci associated with an increased risk of developing IBD.2

Beside these identified genetic loci that provide little contribution to explain IBD hereditability, the number of monogenic diseases presenting IBD-like symptoms is however continuously increasing. These monogenic diseases usually exhibit very early onset and very severe symptoms; in addition, they are often unresponsive to common drugs (anti-inflammatory and immunosuppressive treatments, such as anti-TNFα).

In his article1 Uhlig reports that children with very early onset of bowel inflammation may present a different phenotype and a different genetic architecture. In particular, these children can be classified either as classical IBD patients or as patients suffering from monogenic diseases, the latter also carrying a high number of genetic variants associated with susceptibility to develop IBD. In this regard, we wish to focus the attention on six patients suffering from mevalonate kinase deficiency (MKD, OMIM #260920), diagnosed during the first year of life and followed-up at the Institute for Maternal and Child Health—IRCCS ‘Burlo Garofolo’ (Trieste, Italy). MKD, caused by inherited recessive mutations in the mevalonate kinase gene (MVK), is characterised by febrile attacks, often associated with abdominal pain, diarrhoea and vomiting; it can be considered as an auto-inflammatory defect predisposing to IBD-like intestinal inflammation.3 4 The six MKD patients were homozygous and/or heterozygous for missense mutations on the MVK gene (table 1).
from genome-wide association studies, and in genes responsible for monogenic intestinal diseases. Most of these genes encode for molecules of the innate or adaptive immunity (interleukin (IL)-23R, IL-10, IL-12B and STAT3) and for molecules which are fundamental for intestinal homeostasis (MUC4, GUCY2C, PTPN2, HNF4A and ADAM17). An extended supplementary table containing more detailed information about each patient’s variants is available (https://drive.google.com/file/d/0B6i2AbI03zLYXEyMDRjVGrhBE/edit?usp=sharing.)

The different ‘IBD-associated’ variants, as identified in MKD patients with several combinations in both homozygous and heterozygous states, could account for the presence of abdominal symptoms and inflammation. Hence, we would like to reinforce the hypothesis of a shared genetic background between early onset IBD and MKD, which accounts for the common clinical and phenotypic features characterising the diseases.

Anna Monica Bianco,1 Martina Girardelli,1 Diego Vozzi,1 Sergio Crovella,2 Giulio Kleiner,1 Annalisa Marcuzzi1

1Health Genetics Unit, Institute for Maternal and Child Health—IRCCS “Burlo Garofolo”, Trieste 65/1-34137, Italy; annalisa.marcuzzi@burlo.trieste.it
2Medicine, Surgery and Health Sciences Department, University of Trieste, Trieste, Italy

Correspondence to Dr Annalisa Marcuzzi, Health Genetics Unit, Institute for Maternal and Child Health—IRCCS “Burlo Garofolo”, Via dell’Istria, Trieste 65/1-34137, Italy; annalisa.marcuzzi@burlo.trieste.it

Contributors AM, AMB and SC conceived and designed the study; AMB and MG analysed and interpreted the data and draw tables; DV and AMB performed whole genome sequencing bioinformatic analyses; SC, AM and GK redacted the manuscript; GK and MG revised the manuscript for language and style. All authors have read and approved the final version of this manuscript.

Funding This study was supported by a grant from the Institute for Maternal and Child Health—IRCCS “Burlo Garofolo”—Trieste, Italy (RC 42/2011).

Competing interests None.

Patient consent Obtained.

Ethics approval Independent Bioethics Committee of the IRCCS “Burlo Garofolo”.

Provenance and peer review Not commissioned; internally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/


Received 6 December 2013
Revised 27 December 2013
Accepted 30 December 2013
Published Online First 14 February 2014

doi:10.1136/gutjnl-2013-306555

REFERENCES